{"cik":1919246,"taxonomy":"us-gaap","tag":"AllocatedShareBasedCompensationExpense","label":"Share-based Payment Arrangement, Expense","description":"Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.","entityName":"Pelthos Therapeutics Inc.","units":{"USD":[{"start":"2024-01-01","end":"2024-12-31","val":1560000,"accn":"0001919246-26-000013","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-19","frame":"CY2024"},{"start":"2025-01-01","end":"2025-03-31","val":456000,"accn":"0001919246-26-000070","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-14"},{"start":"2025-01-01","end":"2025-03-31","val":456000,"accn":"0001919246-26-000111","fy":2026,"fp":"Q1","form":"10-Q/A","filed":"2026-08-13","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":850000,"accn":"0001919246-26-000113","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13"},{"start":"2025-04-01","end":"2025-06-30","val":394000,"accn":"0001919246-26-000113","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13","frame":"CY2025Q2"},{"start":"2025-01-01","end":"2025-12-31","val":5461000,"accn":"0001919246-26-000013","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-19","frame":"CY2025"},{"start":"2026-01-01","end":"2026-03-31","val":1908000,"accn":"0001919246-26-000070","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-14"},{"start":"2026-01-01","end":"2026-03-31","val":1908000,"accn":"0001919246-26-000111","fy":2026,"fp":"Q1","form":"10-Q/A","filed":"2026-08-13","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":4668000,"accn":"0001919246-26-000113","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13"},{"start":"2026-04-01","end":"2026-06-30","val":2760000,"accn":"0001919246-26-000113","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13","frame":"CY2026Q2"}]}}